ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
F/m Emerald Life Sciences Innovation ETF
47.80
+0.3549
0.75%
盘后:
47.90
0.1047
+0.22%
19:30 EDT
成交量:
3,080
成交额:
14.77万
市值:
1.32亿
市盈率:
- -
高:
48.06
开:
47.84
低:
47.78
收:
47.44
52周最高:
48.78
52周最低:
27.34
股本:
275.70万
流通股本:
275.70万
量比:
0.73
换手率:
0.11%
股息:
- -
股息率:
- -
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻资讯
第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司
路透中文
·
08/19
中国银河证券:实验动物为创新药研发刚需 小鼠+猴双主线高景气
智通财经
·
08/14
美银证券:中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价
新浪港股
·
08/13
百花医药股价严重异常波动:主营小分子化学仿制药CRO业务 不涉及创新药研发
央广财经
·
08/12
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/LFSC"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":47.7953,"timestamp":1787342400000,"preClose":47.4404,"halted":0,"volume":3080,"hourTrading":{"tag":"盘后","latestPrice":47.9,"preClose":47.7953,"latestTime":"19:30 EDT","volume":7,"amount":334.5671,"timestamp":1787355006986,"change":0.1047,"changeRate":0.002191,"amplitude":0},"delay":0,"changeRate":0.00748096559050937,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"未开盘","change":0.3549,"latestTime":"08-21 16:00:00 EDT","open":47.84,"high":48.06,"low":47.78,"amount":147728.966,"amplitude":0.005902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":47.4404,"sharesOutstanding":2657035,"nav":47.42,"aum":130738599.7,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":47.9,"preClose":47.7953,"latestTime":"19:30 EDT","volume":7,"amount":334.5671,"timestamp":1787355006986,"change":0.1047,"changeRate":0.002191,"amplitude":0},"volumeRatio":0.7335079553807967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7335079553807967,"shares":2757035,"dividePrice":0,"high":48.06,"amplitude":0.005902,"preClose":47.4404,"low":47.78,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":47.7953,"eps":0,"divideRate":0,"volume":3080,"delay":0,"ttmEps":0,"open":47.84,"prevYearClose":36.6147,"prevWeekClose":47.0833,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.0833,"twentyDayClose":45.1004,"sixtyDayClose":39.0706},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660421558","title":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421558","media":"路透中文","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421558?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 22:49","pubTimestamp":1787150961,"startTime":"0","endTime":"0","summary":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司在第4至5段中补充了谢菲尔德联队的声明路透伦敦8月19日-谢菲尔德联队前所有者周三获准申请,将清算该公司——该公司在2024年收购了这支英冠球队。谢菲尔德联队表示,高等法院的裁决对俱乐部而言并非问题。但今年6月,谢菲尔德联队表示1919 Partners LLC是该俱乐部的母公司,对此,United World本周表示,此举“似乎是试图逃避向CSBL的债权人付款”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","GDOC","BK4535","GNOM","LU0109394709.USD","GH","GNMX","HELX","BK4551","BK4588","LFSC","EKG","FFOX","LU0320765992.SGD","PTH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券:实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中国银河证券发布研报称,实验动物为创新药研发刚需,行业壁垒深厚,两大细分赛道具备中长期成长逻辑:人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强,短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK1147","PBE","IBB","BIOY","161027","BBP","APXH","SBIO","BK0188","BK0276","BK4585","XLVI","WRND","GSKH","601881","BK1564","LFSC","06881","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美银证券:中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称,受惠上半年全球及中国生物科技一级市场融资表现强劲,加上创新药对外授权交易持续活跃,预期研发活动将进一步加快,中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元,药明康德A股目标价由177.8元人民币至210.5元人民币,维持“买入”评级,因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%,经调整纯利预测亦上调介乎3%至7%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IDNA","WX","SURI","02359","APXH","PSIL","CXO","XBIX","BBC","SMCO","161027","603259","LFSC","FHLC","MEDI","IBRN","PSCH","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动:主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日,百花医药(维权)(600721.SH)发布公告称,公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%,根据上交所的有关规定,属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业,不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元,同比下降30.68%,归属于上市公司股东的净利润664.27万元,同比下降67.94%。目前公司主营业务未发生重大变化,市场环境、行业政策没有发生重大调整,股价短期内连续上涨,涨幅与公司经营情况严重偏离。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","BIOY","BK0102","BK4588","GSKH","LFSC","GDOC","SBIO","BK4585","IBB","WRND","600721","PBE","BK0216","BBP","XLVI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LFSC\",params:#limit:6,delay:false,,,undefined,":[]}}